Cadence Pharmaceuticals Inc

Cadence Pharmaceuticals — Investor Presentation (June 2011)

27 slides from Cadence Pharmaceuticals's investor presentation, Jun 8, 2011

  1. Slide 1: Corporate Overview

    Corporate Overview Improving the lives of hospitalized patients June 2011 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    Forward-looking statements © 2011 Cadence Pharmaceuticals, Inc. All rights reserved. This presentation includes forward-looking statements, which are based on our current beliefs and expectations. Such statements include, without limitation, statements regarding: the anticipated U.S. market opportun

  3. Slide 3: Cadence: Hospital-focused specialty pharmaceutical company

    Cadence: Hospital-focused specialty pharmaceutical company OFIRMEV ® launched with broad pain and fever indication in January 2011 – Rapid formulary adoption demonstrated – Established hospital sales team provides a core platform for the acquisition of additional products – Management team with sign

  4. Slide 4: OFIRMEV (acetaminophen) injection product overview

    OFIRMEV ® : OFIRMEV (acetaminophen) injection – Proprietary IV acetaminophen formulation – First and only IV formulation of acetaminophen approved in the United States – New class of IV medication • non-narcotic / opioid • non-NSAID – Same formulation of IV acetaminophen marketed by BMS in Europe si

  5. Slide 5: Indication supports message

    OFIRMEV ® : Broad Indication • Mild to moderate pain • Moderate to severe pain with adjunctive opioids • Reduction of fever • Adults and children 2 and older Message • Significant pain relief • Reduced opioid consumption* • Improved patient satisfaction • Established safety profile * Clinical benefi

  6. Slide 6: Strong foundation for commercial success

    OFIRMEV ® : Effective Pain Control Experienced Hospital Sales Force Economic Value • Sales force average >10 years hospital selling experience • Extensive relationships, significant overlap with prior territory • Substantial hospital commercial experience throughout management – CEO > 25 years, CCO

  7. Slide 7: Rapid formulary adoption

    OFIRMEV ® : Rapid formulary adoption – On formulary in 675 hospitals in first 15 weeks of launch – Mix of formulary wins is representative of overall target market – Includes major academic medical centers and large community healthcare systems Most hospitals approved OFIRMEV without restriction – A

  8. Slide 8: Multi-step launch process

    Hospital products: Regulatory Approval Physician Access Formulary Access multi-step launch process

  9. Slide 9: Adoption process

    Phase III Increase Doses Per Patient Phase II Broaden Physician Utilization Phase I Create Access OFIRMEV ® : adoption process

  10. Slide 10: Vial sales off to strong start

    OFIRMEV ® : Vial* Sales of Comparable New Hospital Product Launches (Launches Over Last 5 Years and Cubicin) 20,000 40,000 60,000 80,000 100,000 120,000 Month Post Launch OFIRMEV (1-11) CUBICIN** (11-03) TEFLARO (1-11) DORIBAX (10-07) CLEVIPREX (9-08) VAPRISOL (3-06) VIBATIV (10-09) LUSEDRA (11-09)

  11. Slide 11: Limitations of other IV pain therapies

    Limitations of other IV pain therapies Opioids NSAIDs Sedation Nausea Vomiting Constipation Headache Cognitive impairment Respiratory depression Black Box Warning Bleeding GI complications Kidney complications Cardiovascular risks Prolonged recovery Increased length of stay Higher costs to the insti

  12. Slide 12: The norms: multi-modal analgesia

    Pain Intensity Current US Approach Current EU Approach Multi-modal analgesia: Severe Opioids IV acetaminophen + opioids Moderate Opioids IV acetaminophen +/- opioids* Mild Opioids IV acetaminophen * First post operative analgesic drug, then add opioids if necessary the norms

  13. Slide 13: Pivotal acute pain clinical trial

    IV acetaminophen placebo p-value Sinatra Study: IV acetaminophen placebo p-value Sinatra, et al. Anesthesiology, V 102, No. 4, April 2005. Weighted sums of pain relief over 6hrs 6.6 2.2 <0.05 Patient Satisfaction (Good/excellent – hrs) 41% 23% <0.01 Morphine consumption over 24 hrs** 38.3 mg (33% )

  14. Slide 14: Established safety profile

    OFIRMEV ® : % of adult patients with AST/ALT elevations in five repeat-dose clinical trials ALT > 3x ULN > 5x ULN AST > 3x ULN > 5x ULN (n=379) Placebo (n=402) IV APAP 1.1% (n=4) 0.3% (n=1) 1.7% (n=6) 0.6% (n=2) 1.0% (n=4) 0.5% (n=2) 1.1% (n=4) 0.8% (n=3) * Data from a pooled analysis of 5 multiple

  15. Slide 15: Consistent opioid reduction across studies

    Pain Intensity Opioid Reduction* Time p Value Consistent opioid reduction across studies Severe 33% 24h <0.01 61% 24h <0.05 Moderate 53% 0-6h 0.016 Mild 86% 24h <0.001 78% 24h <0.01 *Reduction in number of patients requiring analgesic rescue with ketorolac and fentanyl 1) Sinatra, et al, 2005; 2) Me

  16. Slide 16: Economic value

    OFIRMEV ® : Placebo-controlled studies using IV acetaminophen demonstrated results that may be associated with possible hospital cost savings: – Decreased opioid consumption * • Total hip/knee replacement (1) • Total hip replacement (2, 3) • Adult tonsillectomy (4) • Endoscopic thyroidectomy (5) – D

  17. Slide 17: EU market leader

    IV acetaminophen: Source: IMS Data *(SOM – Share of market) • >20% unit share of injectable analgesic market EU market leader

  18. Slide 18: Europe: 78% receive IV acetaminophen post-op

    Europe: % of Inpatients Given Each of the Following Treatments Post-operatively PharmaSavvy market research 2009. n=60 anesthetists (commissioned by Cadence Pharmaceuticals) 78% receive IV acetaminophen post-op

  19. Slide 19: US: >70% may receive IV acetaminophen post-op

    US: Post-op inpatient treatment assignments assuming availability of IV acetaminophen* (Product X) PharmaSavvy market research 2009. n=102 (52 surgeons, 50 anesthesiologists) * Based on target product profile similar to OFIRMEV™ approved indications >70% may receive IV acetaminophen post-op

  20. Slide 20: Early adoption

    OFIRMEV ® : ATU Research 10/2010 Base: Anesthesiologists and surgeons Q55. How soon after FDA approval would you expect to first use Product X (IV acetaminophen)? Virtually all respondents expect to use OFIRMEV at some point. About half of respondents across specialties would expect to try OFIRMEV w

  21. Slide 21: The UK experience: an appropriate model

    The UK experience: UK treatment paradigms for moderate and acute pain are similar to those in the US – Higher opioid than NSAID usage – Multimodal pain therapy Perfalgan, BMY’s IV acetaminophen – Launched in 2004 – Has taken approximately 35% market share – Most share taken from opioids, some from N

  22. Slide 22: Acetaminophen combinations dominate

    Oral opioids: Opioid-acetaminophen combinations Opioid-only products Opioid-NSAID combinations 73% 25% 1% Source: IMS data, 2008. 73% of oral opioid doses sold in U.S. contain acetaminophen Approximately 14.4 billion total doses sold in 2008 Acetaminophen + hydrocodone is the most frequently dispens

  23. Slide 23: US market opportunity

    OFIRMEV ® : US and EU injectable analgesics markets are similarly sized Approximately 87 million IV acetaminophen units sold in Europe in 2009 Continued EU market expansion after introduction of IV acetaminophen List price $10.75 per vial; net price approximately $10.05 per vial Sources: IMS data, c

  24. Slide 24: Injectable analgesic market: highly concentrated

    Injectable analgesic market: Source: WoltersKluwer Non-Retail Outlet Data, June 2009 MAT *Injectable analgesics consist of USCs 02221, 02211, 02131, 02231 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 1,000 2,000 3,000 4,000 5,000 6,000 Number of Hospitals The top 1,874 (28%) hospitals generated 80% o

  25. Slide 25: Experienced, Seasoned, Tested Sales Organization

    Experienced, Seasoned, Tested Sales Organization 147 Hospital Sales Specialists – >10 years hospital selling experience – 90% resigned to join Cadence – Extensive relationships, 70% overlap with prior territory Deep hospital commercial experience – CEO > 25 years – CCO > 15 years – VP Sales > 25 yea

  26. Slide 26: Financial position

    Cadence: 12 Months Ended 12/31/10 (MM) 3 Months Ended 3/31/11 (MM) Operating expenses $ 54.9 $ 22.7 Cash, cash equivalents & short-term investments $134.1 $109.0 (1) Shares outstanding 63.1 63.3 (1) Does not include a $5.3 million upfront payment received in April 2011 under a data license agreement

  27. Slide 27: OFIRMEV (acetaminophen) injection product overview

    OFIRMEV ® : OFIRMEV (acetaminophen) injection – Proprietary IV acetaminophen formulation – First and only IV formulation of acetaminophen approved in the United States – New Class of IV Analgesic OFIRMEV launched with broad pain and fever indication in January 2011 – Rapid formulary adoption demonst

Cadence Pharmaceuticals — Investor Presentation (June 2011) on 6ix